The latest episode of a BioSpace podcast explores emerging approaches in the treatment of celiac disease, moving beyond the current reliance on gluten-free diets. The discussion brings together Dr. Joe Murray from the Mayo Clinic, Marilyn Geller, CEO of the Celiac Disease Foundation, and Dr. Paul Lizzul, chief medical officer at AnaptysBio.
The experts address ongoing challenges faced by individuals with celiac disease, noting that while gluten-free diets are currently the mainstay of management, they have significant limitations and there are no FDA-approved therapies available.
A key focus of the conversation is ANB033, a new CD122 antagonist being developed by AnaptysBio. According to those involved in its development, this investigational therapy aims to modulate IL-2/IL-15 signaling pathways. Early preclinical studies indicate potential for reducing inflammation and mucosal injury associated with celiac disease.
The podcast also outlines details about an ongoing Phase 1b clinical trial for ANB033. This includes information about patient selection—specifically those with persistent symptoms—the use of gluten-challenge models to test efficacy, and primary safety outcomes observed during the earlier Phase Ia study. The discussion further touches on other therapies targeting IL-15 currently in development and emphasizes the need to gather meaningful data from patients' real-life experiences.
"This episode is presented in partnership with AnaptysBio."
"Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations."
Jennifer Smith-Parker, Director of Insights at BioSpace, hosted the conversation.
